=Compugen (CGEN) : CGEN-15032 as a target for the development of first-in-class cancer therapy

Compugen discloses new data demonstrating the potential of CGEN-15032 as a target for the development of first-in-class cancer therapy

CGEN-15032 is a novel myeloid and epithelial immuno-oncology target, which may serve as an immuno-suppressive target within the tumor microenvironment. Addressing the immuno-suppressive environment of the tumor through myeloid drug targets has the potential for developing treatments that may expand the patient population responsive to current treatments.

• The data, demonstrating the target's immunomodulatory effect and its effect on tumor growth, were generated as part of the research collaboration with the Johns Hopkins University School of Medicine (JHU), under the direction of Prof. Drew Pardoll, MD, PhD, Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and Chairman of Compugen's Scientific Advisory Board.
• Compugen also announced today the extension of its multi-year immuno-oncology research collaboration with JHU. The research collaboration, originally announced in December 2014 is now expanded to include new additional targets discovered by Compugen which have the potential to serve as a basis for the development of cancer immunotherapy treatments.